Recently Completed Research Studies

Below is an archive of some of the research studies we conducted in the Penn Scleroderma Center. All studies on this page are closed to enrollment. For more detailed information about these studies, please look up the given NCT# in


Full Name: Phase 1 Open-Label Study to Determine the Safety and Tolerability of AVID200 in Patients with Diffuse Cutaneous Systemic Sclerosis
Study Dates: 2018-2020
NCT #: NCT03831438
Study Findings: Study results are pending.


Full Name: Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
Study Dates: 2015-2019
NCT #: NCT02161406
Study Findings: Abatacept was well-tolerated, but change in the modified Rodnan skin thickness score (MRSS) was not statistically significant. Secondary outcome measures, including gene expression subsets, showed evidence in support of abatacept.


Full Name: Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Study Dates: 2018-2020
NCT #: NCT03398837
Study Findings: Data showed no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo, both added to background drug therapy.


Full Name: Study to Assess the Efficacy, Safety, and Tolerability of Macitentan in Patients with Ischemic Digital Ulcers Associated with Systemic Sclerosis
Study Dates: 2012-2013
NCT #: NCT01474109
Study Findings: Although the risks of the study drug appear modest, the possibility of any benefit appears even smaller and additional data cannot be expected to result in a positive primary outcome measure.

SSc with ILD

Full Name: Study of Pomalidomide in Patients with Systemic Sclerosis with Interstitial Lung Disease
Study Dates: 2012-2014
NCT #: NCT01559129
Study Findings: Study results were neither positive nor negative because too few subjects were enrolled to make meaningful conclusions.


Full Name: Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma
Study Dates: 2012-2016
NCT #: NCT00377949
Study Findings: This study confirmed that high-risk factors including a low DLco, high FVC/DLco, exercise-induced hypoxia and entry echo sPAP > 40 do predict future pulmonary hypertension.


Full Name: Phase 3 Study Evaluating Intravenous Iloprost in Systemic Sclerosis with Symptomatic Digital Ischemic Episode
Study Dates: 2019-2021
NCT #: NCT04040322
Study Findings: Study results are pending.